Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...
Results from the phase 3 PEACE-3 study found that a combination therapy showed higher benefits for patients with bone ...
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...
If you're delving into the world of bodybuilding, chances are you've heard of Ostarine (MK-2866). It's one of the most ...
12d
Explore our latest breakthroughs in metastatic prostate cancer research. Learn more about our innovative pipeline today! @ ...
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...
In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...
Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback